These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24239384)

  • 1. Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice.
    Rothman SM; Griffioen KJ; Fishbein KW; Spencer RG; Makrogiannis S; Cong WN; Martin B; Mattson MP
    Neurobiol Aging; 2014 May; 35(5):1153-61. PubMed ID: 24239384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice.
    Rothman SM; Griffioen KJ; Vranis N; Ladenheim B; Cong WN; Cadet JL; Haran J; Martin B; Mattson MP
    J Parkinsons Dis; 2013; 3(2):215-29. PubMed ID: 23938351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
    Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
    Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.
    Lee SY; Jeong S; Kim J; Chung SK
    Stem Cell Res; 2018 Jul; 30():145-149. PubMed ID: 29906669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
    Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
    CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein-Induced Destabilized BMAL1 mRNA Leads to Circadian Rhythm Disruption in Parkinson's Disease.
    Liu JY; Xue J; Wang F; Wang YL; Dong WL
    Neurotox Res; 2023 Apr; 41(2):177-186. PubMed ID: 36662411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines.
    Woerman AL; Oehler A; Kazmi SA; Lee J; Halliday GM; Middleton LT; Gentleman SM; Mordes DA; Spina S; Grinberg LT; Olson SH; Prusiner SB
    Acta Neuropathol; 2019 Mar; 137(3):437-454. PubMed ID: 30690664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.
    Stanojlovic M; Pallais JP; Kotz CM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
    Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
    Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
    Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
    [No Abstract]   [Full Text] [Related]  

  • 14. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
    McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
    Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant α-Synuclein.
    Pfeffer M; Zimmermann Z; Gispert S; Auburger G; Korf HW; von Gall C
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29865270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodromal sensory neuropathy in Pink1
    Valek L; Tran B; Wilken-Schmitz A; Trautmann S; Heidler J; Schmid T; Brüne B; Thomas D; Deller T; Geisslinger G; Auburger G; Tegeder I
    Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1060-1079. PubMed ID: 33974284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
    Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
    J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.